

CLAIMS

1. A pharmaceutical combination comprising:

(A) an anti-LY75 antibody, or an antigen-binding portion thereof, said antibody or portion thereof comprising:

a) a heavy chain variable region comprising:

i) a first vhCDR comprising SEQ ID NO: 5;

ii) a second vhCDR comprising SEQ ID NO: 6; and

iii) a third vhCDR comprising SEQ ID NO: 7; and

b) a light chain variable region comprising:

i) a first vlCDR comprising SEQ ID NO: 8;

ii) a second vlCDR comprising SEQ ID NO: 9; and

iii) a third vlCDR comprising SEQ ID NO: 10;

optionally wherein any one or more of the above SEQ ID NOs independently comprise one or two amino acid substitutions,

wherein the anti-LY75 antibody or an antigen-binding portion thereof further comprises a covalently-attached moiety, and wherein said moiety is a drug; and

(B) Rituximab;

wherein the pharmaceutical combination is in the form of a combined preparation for simultaneous, separate or sequential use.

2. The pharmaceutical combination as claimed in claim 1, wherein any one or more of SEQ ID NOs: 5-10 independently comprise one or two conservative amino acid substitutions.

3. The pharmaceutical combination as claimed in claim 1 or claim 2, wherein the antibody or antigen-binding portion thereof is capable of being internalised.

4. The pharmaceutical combination as claimed in any one of claims 1 to 3, wherein the anti-LY75 antibody or an antigen-binding portion thereof comprises a heavy chain variable region having at least 80%, 85%, 90%, 95%, 99% or 100% amino acid sequence identity to

SEQ ID NO: 1 and a light chain variable region having at least 80%, 85%, 90%, 95%, 99% or 100% amino acid sequence identity to SEQ ID NO: 2.

5 5. The pharmaceutical combination as claimed in any one of claims 1 to 4, wherein the anti-LY75 antibody is a human IgG1 monoclonal antibody.

6. The pharmaceutical combination according to any one of claims 1 to 5, wherein said drug is a maytansinoid or a derivative thereof.

10 7. The pharmaceutical combination according to claim 6, wherein said drug is DM4 or DM1.

15 8. The pharmaceutical combination according to any one of claims 1 to 7, wherein (A) and/or (B) additionally comprise one or more pharmaceutically-acceptable diluents, excipients or carriers.

9. A kit comprising:

- 20 (i) an expression vector comprising DNA encoding the heavy and light chains of the anti-LY75 antibody or antigen-binding portion thereof of claim 1; and
(ii) an expression vector comprising DNA encoding the heavy and light chains of Rituximab.

10. A host cell comprising expression vectors comprising nucleic acids encoding:

- 25 (i) the heavy chain of the anti-LY75 antibody or antigen-binding portion thereof of claim 1;
(ii) the light chain of the anti-LY75 antibody or antigen-binding portion thereof of claim 1;
(iii) the heavy chain of Rituximab; and
(iv) the light chain of Rituximab.

30 11. A pharmaceutical combination according to any one of claims 1 to 8, for use in the treatment of cancer, wherein components (A) and (B) are simultaneously, separately or sequentially administered to the patient for the treatment of the cancer.

35 12. The pharmaceutical combination for use according to claim 11, wherein the anti-LY75 antibody or antigen-binding portion thereof is internalized by a cell expressing LY75.

13. The pharmaceutical combination for use according to claim 11 or claim 12, wherein the covalently-attached drug is a maytansinoid.
14. The pharmaceutical combination for use according to claim 13, wherein the
5 maytansinoid is DM4.
15. The pharmaceutical combination for use according to any one of claims 11 to 14, wherein the cancer is diffuse large B-cell lymphoma (DLBCL) or Non-Hodgkin's lymphoma.
- 10 16. Use of components (A) and (B) of the pharmaceutical combination as defined in any one of claims 1 to 8 in the manufacture of a pharmaceutical combination for simultaneous, separate or sequential use for the treatment of cancer.
- 15 17. The use according to claim 16, wherein the anti-LY75 antibody or antigen-binding portion thereof is internalized by a cell expressing LY75.
18. The use according to claim 16 or claim 17, wherein the covalently-attached drug is a maytansinoid.
- 20 19. The use according to claim 18, wherein the maytansinoid is DM4.
20. The use according to any one of claims 16 to 19, wherein the cancer is diffuse large B-cell lymphoma (DLBCL) or Non-Hodgkin's lymphoma.
- 25 21. A pharmaceutical combination according to any one of claims 1 to 8 for use in therapy or for use as a medicament.